載入...
An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs)
Patients suffering from pancreatic neuroendocrine tumors (pNETs) are now candidates to receive novel approved drugs that have demonstrated benefit in disease control rate and delay the time taken for tumor progression in Phase III clinical trials; for example, sunitinib, everolimus and lanreotide. T...
Na minha lista:
| 發表在: | Rare Cancers Ther |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Springer Healthcare
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4837935/ https://ncbi.nlm.nih.gov/pubmed/27182476 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40487-015-0007-6 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|